Hot News @ 藥物

 < Previous page   
Related Keyword:禮來 , 試驗 , 羅氏
Related Concept:美國藥廠禮來中止抗體藥物試驗 , 肺炎療法測試 , 羅氏制藥隱瞞死亡報告 , 藥物在華有售
 
【新冠肺炎】美國禮來暫停抗體療法測試稱有安全憂慮 @ 2020-10-14T20:
美國藥廠禮來公司(Eli Lilly and Company)10月13日宣布,公司旗下獲華府資助的新型冠狀病毒(COVID-19)抗體療程測試因為安全問題而暫停。禮來的.
Keyword:禮來 試驗
Concept:美國藥廠禮來中止抗體藥物試驗 , 肺炎療法測試
@ 2020-10-14T16:
Keyword:禮來
Concept:
中國掌付配發合共2﹒7億份認股權證,占擴大後股本13﹒5% @ 2012-07-13T10:
《經濟通通訊社13日專訊》中國掌付(08047)公布,配發合共2﹒7億份認股權證予四名認購人,發行價連同認購價合共0﹒09元較前收市價折讓12﹒62%。若認股權證所附帶之所有認購權獲悉數行使,可配發2﹒7億股,占擴大後股本約13﹒54%,預期將籌集
Keyword:羅氏
Concept:羅氏制藥隱瞞死亡報告 , 藥物在華有售
 < Previous page   

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.